Exchange & Returns Information
Review Details
(0)
| Generic For | HYDREA |
|---|---|
| Active Ingredient | HYDROXYUREA |
| Strength | 500MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 100 CAPSULES | $ 0.47 | $ 47.00 |
$ 39.95
Apply ZARVY26 (-15%)
You save $ 7.05
|
||
| 2 BOXES - 200 CAPSULES | $ 0.51 | $ 102.00 |
$ 86.70
Apply ZARVY26 (-15%)
You save $ 15.30
|
||
| ★ Best Value 3 BOXES - 300 CAPSULES | $ 0.52 | $ 157.00 |
$ 133.45
Apply ZARVY26 (-15%)
You save $ 23.55
|
Reference information will be available soon.
Cytodrox 500 is an oral chemotherapeutic agent containing 500mg of hydroxyurea. It is widely utilized in the treatment of hematologic malignancies and chronic myeloproliferative disorders. Hydroxyurea acts primarily as a ribonucleotide reductase inhibitor, impeding DNA synthesis in rapidly dividing cells.
This mechanism makes it especially effective in conditions like chronic myeloid leukemia (CML), polycythemia vera, and essential thrombocythemia. Beyond oncology, hydroxyurea has established itself as a standard disease-modifying therapy in sickle cell anemia, where it increases fetal hemoglobin (HbF) production, improving red cell flexibility and reducing clinical complications.
Its affordability, oral administration, and strong clinical efficacy have made it a mainstay in both cancer and hematology treatment paradigms.
AntiCancer Drugs > Chronic Myeloid Leukemia (CML)
Cytodrox 500 is indicated for cytoreduction in CML, especially in patients with extreme leukocytosis or during the initial stabilization phase prior to targeted therapy. It helps manage tumor burden and minimizes complications such as thrombosis and splenomegaly.
AntiCancer Drugs > Polycythemia Vera & Essential Thrombocythemia
Used as first-line treatment in high-risk patients to control hematocrit and platelet counts. It significantly reduces the risk of thrombotic events such as stroke or myocardial infarction. Its favorable cost-effectiveness and oral convenience support long-term use.
DISEASES/SYMPTOMS > Sickle Cell Anemia
Hydroxyurea is a frontline therapy to reduce vaso-occlusive crises, acute chest syndrome, and transfusion dependence. By promoting fetal hemoglobin (HbF) production, it mitigates the polymerization of sickled hemoglobin, thereby improving oxygen delivery and reducing hemolysis. Approved for use in both adult and pediatric patients.
Hydroxyurea inhibits ribonucleotide reductase, a critical enzyme in de novo DNA synthesis, leading to cell cycle arrest at the S phase. This selectively suppresses rapidly proliferating myeloid precursors, offering cytoreductive benefit in CML and other myeloproliferative disorders.
In sickle cell disease, hydroxyurea enhances erythroid progenitor cell production of HbF, which inhibits hemoglobin S polymerization and sickling.
This dual action allows hydroxyurea to bridge oncologic and non-oncologic hematologic treatments, providing both survival and quality-of-life improvements.
Chronic Myelogenous Leukemia (CML)
Dose: Individualized per clinical protocol
Initial daily dose adjusted to WBC count and tolerance
Weekly CBC monitoring is essential
Correct anemia prior to initiation
Folic acid supplementation is recommended
Use: Cytoreductive management in CML patients, especially during disease stabilization or in resource-limited settings
Head and Neck Cancer
Administered orally during concurrent chemoradiation
Dosage individualized per body surface area and protocol
Close hematologic monitoring required
Folic acid support reduces mucosal toxicity
Use: Adjuvant to radiation in locally advanced head and neck squamous cell carcinoma
Sickle Cell Anemia – Adults
Start at 15 mg/kg once daily orally
Titrate by 5 mg/kg/day every 12 weeks
Max: 35 mg/kg/day depending on hematologic tolerance
Monitor CBC every 2 weeks during adjustment phase
Maintain folic acid supplementation
Use: Reduces pain crises, hospitalization, and transfusion needs in adults with recurrent sickle cell episodes
Sickle Cell Anemia – Pediatrics
Start at 20 mg/kg once daily orally
Titrate by 5 mg/kg/day every 8 weeks
Max: 35 mg/kg/day
Tablets may be split for precise dosing
Biweekly monitoring of hematologic parameters
Folic acid recommended throughout treatment
Use: Approved from age 2 for prevention of sickle cell complications in pediatric patients
Administration Tips
Take orally at the same time daily, with or without food
Swallow capsules whole; do not crush or chew
Ensure adequate hydration throughout treatment
Handle with gloves when dispensing due to cytotoxic nature
Do not double dose if a dose is missed
Store below 25°C in a dry, dark environment
Keep away from direct sunlight and moisture
Maintain in original packaging
Keep out of reach of children
Use personal protective equipment (PPE) when handling opened capsules
Common: Myelosuppression (neutropenia, anemia, thrombocytopenia) is dose-limiting; gastrointestinal upset and appetite loss may also occur.
Occasional: Mucositis, skin discoloration, and nail changes can develop with prolonged therapy.
Rare: Leg ulcers, hepatic/renal toxicity, or secondary leukemia may appear after long-term exposure.
Monitoring: Regular CBC, renal, and liver function tests are required to ensure safety.
Management: Interrupt or reduce dose if significant cytopenias or organ toxicity occurs.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
